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Abstract 
Background: Nationwide hospital admissions data series have contributed to a reliable assessment of the changing 
epidemiology of infective endocarditis, even though conclusions are not uniform. We sought to use a recent popula-
tional series to describe the temporal trends on the incidence of infective endocarditis, its clinical characteristics and 
outcome results, in Portugal.
Methods: A nationwide retrospective temporal trend study on the incidence and clinical characterization of patients 
hospitalized with infective endocarditis, between 2010 and 2018.
Results: 7574 patients were hospitalized with infective endocarditis from 2010 to 2018 in Portuguese public hospi-
tals. The average length of hospitalization was 29.3 ± 28.7 days, predominantly men (56.9%), and 47.1% had between 
60 and 79 years old. The most frequent infectious agents involved were Staphylococcus (16.4%) and Streptococcus 
(13.6%). During hospitalization, 12.4% of patients underwent heart valve surgery and 20% of the total cohort died. 
After a 1-year post-discharge follow-up, 13.2% of the total initial cohort had had heart valve surgery and 21.2% in total 
died. The annual incidence of infective endocarditis was 8.31 per 100,000 habitants, being higher in men (9.96 per 
100,000 in males versus 6.82 in females, p < 0.001) and increased with age, peaking at patients 80 years old or older 
(40.62 per 100,000). In-hospital mortality rate significantly increased during the analyzed period, the strongest inde-
pendent predictors being ischemic or hemorrhagic stroke, sepsis, and acute renal failure. Younger age and cardiac 
surgery had a protective effect towards a fatal outcome.
Conclusions: In Portugal, between 2010 and 2018, the incidence of infective endocarditis presented a general 
growth trend with a deceleration in the most recent years. Also, a significant rate of in-hospital complications, a mildly 
lower than expected stable surgical rate and a still high and growing mortality rate were noted.
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Introduction
Infective endocarditis (IE) is an old and rare disease, with 
an annual incidence in populational studies of 4 to 10 
cases per 100,000 per habitants [1]. Indeed, all IE cases 
culminate in hospitalization at some point. And despite 
decades of improvement in the medical and surgical field, 
a persistent substantial rate of complications and mortal-
ity is shown in IE. In fact, worldwide, the intrahospital 
mortality rate varies among different countries, varying 
between 8 and 40% [2]. Several factors may contribute to 
this variation such as the country surveyed, the duration 
of the research, the analyzed time, variations in the popu-
lation studied, considered IE case definition and organi-
zation of the health systems.
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A shift in the epidemiology of endocarditis has been 
noted in the most recent literature [3–5], with older and 
more complex patients, Staphylococcus aureus as an 
important and emerging agent, a growing susceptible 
adult population of patients with congenital heart dis-
ease or intracardiac prosthesis or devices and chronic 
renal failure on dialysis. The diagnostic criteria changed 
in 2000 [6] with the evolution of transesophageal echo-
cardiography and microbiology and in 2015 [7] with the 
inclusion of new imaging diagnostic techniques such 
as 18F-FDG PET/CT. Timing of surgery and antibiotic 
prophylaxis continue to be challenging issues in daily 
practice.
Little information is known about Portugal’s tempo-
ral trends regarding IE incidence and clinical results. 
The main source of evidence regarding the IE situation 
in Portugal arises from single-center hospital surveys 
[8–12] and conclude that it predominantly occurs in 
older male patients, with a predominance of Staphylo-
coccus and Streptococcus species and an apparently high 
rate of intrahospital complications. Nevertheless, several 
questions remain unanswered regarding epidemiological 
and outcome results in patients hospitalized with IE in 
Portugal.
Using populational-based data we aimed to under-
stand the incidence of IE in Portugal, describe its clinical, 
microbiological, complications and outcome results, and 
analyze its evolution between 2010 and 2018.
Methods
Study design and data source
A nationwide retrospective temporal trend study on the 
incidence of IE was performed.
Data were obtained from the Central Administration of 
the Health System of the Portuguese Ministry of Health 
(Administração Central Sistemas Saúde—ACSS-). This 
system contains administrative and clinical data of all 
admissions and discharges to National Health System 
hospitals, which covers almost the whole population of 
Portugal. Until 2014, it only included Portugal Mainland 
public hospitals. From 2015 onwards, it included the 
Madeira and Azores public hospital data. Hospitaliza-
tions in private hospital centers are not included.
The hospital discharge report contains clinical informa-
tion (sex, age, geographical region, hospital institution, 
date of admission and discharge, length of hospitaliza-
tion, disposition—home, unknown, another acute hos-
pital center, palliative care institution, outpatient clinics, 
discharge against medical advice, deceased), a clinical 
diagnosis list (a primary diagnosis and up to nineteen 
secondary diagnoses) and procedures (up to twenty). It 
is completed by the medical team that was responsible 
for the patient during hospitalization. Hospital discharge 
report coding, using the International Classification of 
Diseases (ICD) is then performed by specially trained 
medical staff, based on the medical report and other clin-
ical documents available on the patient’s file.
Until 2016, the 9th Revision Clinical Modification 
(ICD-9-CM) was used to code for diagnosis and proce-
dures. From 2016 to the present day, the 10th Revision 
Clinical Modification (ICD-10-CM) has been used.
Study population and patients
The study population covered patients from all age 
groups, from Mainland Portugal until 2014 and from 
Portugal (mainland and islands Azores and Madeira) 
from 2015 to 2018.
In this study, we retrospectively identified all cases of 
incident IE episodes analyzing all hospital episodes of 
patients with a discharge diagnosis of infective endo-
carditis (ICD-9-CM codes 421.0, 421.1, 421.9 and 424.9; 
ICD-10-CM I33.0, I33.9, I38 and I39) between 1st Janu-
ary 2010 and 31st December 2018. Patients admitted 
in 2009 with a diagnosis of IE were removed (prevalent 
cases). Day case episodes were also excluded.
IE cases were recognized through the identification of 
all episodes of hospitalization that contained an IE com-
patible code as the primary or secondary diagnosis. The 
use of modified Duke criteria [13] has been the main-
stay for the diagnosis of IE in Portugal, with a gradual 
integration of the newer imaging modalities since 2015 
as per European scientific guidelines indication [7].To 
avoid overcounting, we identified the first episode of 
each patient with an IE compatible code for the analyzed 
period. From this group of patients, we identified those 
that were transferred to another acute care hospital (a 
7.9% of the total cohort, with zero- or one-day difference 
between the discharge date and the subsequent admis-
sion for IE), guaranteeing combination between sub-
sequent episode to the previous one so that all patients 
were considered to have a single episode/hospitalization 
for IE.
All subsequent hospital episodes following one year 
after the first hospitalization for IE were analyzed to 
identify hospital readmissions and the performance of 
cardiac surgery.
Variables
For incident IE episodes, clinical information (sex, age, 
year of discharge length of hospitalization), previous 
heart history and comorbidities (diabetes mellitus, non-
rheumatic valve disease, rheumatic valve disease, arterial 
hypertension, chronic renal disease, chronic coronary 
artery disease, cancer, HIV, cardiac devices and heart 
valve prosthesis, atrial fibrillation, chronic liver disease, 
chronic obstructive lung disease, use of opioid drugs, 
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congenital heart disease), microorganisms (Staphylococ-
cus, Streptococcus, Enterococcus, Gram-negative, anaer-
obes, fungus, Brucella), IE compatible complications 
(heart failure, embolic stroke, ischemic stroke, transient 
ischemic accident, septic shock, splenic abscess, acute 
renal failure, acute coronary syndrome, central nervous 
system abscess or meningitis), cardiac surgery, and intra-
hospital death were collected using the ICD-9 and ICD-
10 codes—see Additional file 1: Table S1.
Outcomes
For each year, the incidence of IE in Portugal was esti-
mated as the number of new cases per year and was 
expressed as 100,000 inhabitants/year and was calculated 
as a nine-year average. Annual mainland Portuguese pop-
ulation until 2014 and total Portuguese population after 
2014 (denominator) were obtained from census popula-
tion (2011) or estimates for intercensal years, at Statistics 
Portugal [the Portuguese National Instituto of Statistics 
(INE)] database.
The annual incidence was also assessed for the age 
group (< 18; 18–39; 40–49; 50–59; 60–79 and ≥ 80 years 
old) and sex-specific groups.
The size of the population (total, sex and group age-
specific) of Portugal was obtained from the informa-
tion line of the National Institute of Statistics (Instituto 
Nacional Estatística—INE—www.ine.pt) and corre-
sponds to the estimates of the resident population at the 
end of the year, for each year of the study. The Portuguese 
population was 10,562,178 in 2011 (National Census per-
formed in 2011) decreasing to 10,276,617 in 2018 [14].
Among patients hospitalized with incident IE, the 
annual rate of in-hospital mortality was found.
From the analysis of subsequent hospital readmissions 
for up to one year, the rates of total cardiac surgery per-
formed on the cohort, 30  day and 1-year hospital read-
mission rates and hospital death within one year of initial 
admission were also obtained.
Statistics
Continuous variables were presented as mean ± standard 
deviation and categorical variables expressed as frequen-
cies and percentages. The comparison between continu-
ous variables was done through t Student’s test or Mann 
Whitney test, and the comparison between categorical 
variables was calculated with the chi-square test or Fisher 
exact test. Linear by Linear association was performed to 
test for a linear trend during the analyzed period.
To assess the factors associated with in-hospital surgi-
cal intervention and in-hospital mortality, the inferential 
analysis was performed using multiple logistic regres-
sion (a generalized linear model using Poisson distribu-
tion and the logit link function). The Stepwise (Forward) 
method based on the Akaike information criterion mini-
mization was used for the selection of variables included 
in the model. The adjusted odds ratio, as well as the 95% 
Confidence interval (CI 95%), were estimated for each 
variable included in the regression model.
The temporal trend analysis of IE incidence (total, by 
age-group, and by gender) was performed using Linear 
Correlation Coefficient, linear and quadratic regression, 
using the year variable and its square.
All tests were 2-tailed. The level of significance was set 
to α = 0.05.
The data were analyzed using IBM SPSS Statistics for 
Windows version 24 software (IBM Corp., Armonk, NY, 
USA).
Results
Study population demographic, medical background 
and in‑hospital outcomes
7574 patients were admitted with incident IE from 2010 
to 2018 in Portugal, with 8172 episodes of hospitaliza-
tion—see Table  1. The average length of hospitaliza-
tion was 29.3 ± 28.7  days (minimum 1 and maximum 
439  days, median 21  days). The majority were male 
(56.9%), and nearly half of the cohort had between 60 and 
79  years old. A relevant prevalence of diabetes (26.6%), 
arterial hypertension (37.3%), atrial fibrillation (24.8%) 
and heart valve disease (30.4%) were noted.
A microorganism was coded in 49.5% of the incident 
episodes of IE. The most frequent infectious agents 
involved were Staphylococcus (16.4%) and Streptococcus 
(13.6%), followed by gram-negative bacteria (11.9%).
During the first hospitalization for IE, 3995 patients 
(52.7%) had an in-hospital complication. The most fre-
quent IE related complication were heart failure (29.5%), 
followed by sepsis (12.4%), neurologic events (ischemic 
stroke affected nearly 10% of the total cohort) and acute 
renal failure (10.8%)—see Table 2.
During the incident hospitalization for IE, 937 (12.4%) 
patients received heart valve surgery.
Of the patients with incident IE, 5058 (66.8%) were 
discharged home, 64 (1%) were transferred to a rehabili-
tation or palliative care institution and in 939 patients 
(12.4%) the destination post discharge is unidentified 
(unknown or discharge against medical advice). One-fifth 
of the total cohort (1513 patients) died.
During the studied period, a reduction was noted in 
the rate of younger patients admitted with IE (particu-
larly between 18 and 39 years old); as the opposite, an 
increase was noted in the older patients (octogenar-
ians). Also, a trend towards an increase in comorbidi-
ties such as diabetes mellitus, arterial hypertension, 
atrial fibrillation, chronic renal failure and cancer was 
noted—see Table  3. Likewise, the proportion of IE 
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related to cardiac valve prosthesis and intracardiac 
devices rose. IE caused by Staphylococcus spp. stead-
ily increased overtime whereas Streptococcus spp. pre-
sented a mild overall decline. Regarding IE-related 
complications, there was overall increment overtime, 
mainly noted with systemic embolism and acute renal 
failure rates. The in-hospital surgical rate remained 
stable during the observed period, oscillating between 
10.2 and 14.6%—see Fig. 1.
599 patients were readmitted during the first-year post-
discharge after an incident episode of IE (9.8% of the 
total cohort that survived the first hospitalization)—see 
Table 2. More than half of these patients were readmitted 
during the first 30  days post-discharge. During the first 
year follow up 61 more patients had heart valve surgery 
totalizing 13.2% of the total cohort and 98 patients died 
(totalizing 21.2% of the total initial cohort).
Incidence rate and temporal trend of IE in Portugal
In Portugal, from 2010 to 2018, the incidence of IE varied 
between 6.25 cases and 9.35 per 100,000—see Table  4. 
The average annual incidence was 8.31 per 100,000 
inhabitants (95% CI 7.59–9.03).
IE was more frequent in males [9.96 per 100,000 (95% 
CI 9.14–10.78) versus 6.82 (95% 6.15–7.51) in females, 
p < 0.001], with an annual ratio male/female varying 
between 1.3 and 1.6—see Table 4 and Fig. 2.
This incidence also was higher with age, peaking at 
patients in the oldest age group (with 80  years old or 
older) [40.62 per 100,000 (95% CI 34.66–46.59)]—see 
Table 4 and Fig. 3a.
Using Pearson’s linear correlation coefficient and linear 
and quadratic regression analysis on the global incidence 
of IE in Portugal during the nine years, a globally upper 
trend was noted with a maximum value occurring in 
Table 1 Demographic, medical background and infectious 
agents involved in IE hospitalizations
CABG coronary artery bypass graft, COPD Chronic Obstructive Pulmonary 
Disease, CRF chronic renal failure, HIV human immunodeficiency virus, PCI 
percutaneous coronary intervention
2010–2018
Number of patients, n 7574
Male, n (%) 4308 (56.9)
Age, years (SD) 68.3 ± 17.3
Age groups, n (%)
 < 18 91 (1.2)
 18–39 503 (6.6)
 40–59 1253 (16.5)
 60–79 3565 (47.1)
 ≥ 80 2162 (28.5)
Length of hospital stay, days (SD) 29.3 ± 28.7
Median 21
Medical background, n (%)
 Diabetes mellitus 2016 (26.6)
 Arterial hypertension 2828 (37.3)
 Atrial fibrillation 1876 (24.8)
 HIV 133 (1.8)
 CRF 887 (11.7)
 CRF on Hemodialysis 324 (4.3)
 Non-rheumatic cardiac valve disease 1590 (21.0)
 Rheumatic valve disease 709 (9.4)
 Cardiac valve prosthesis 914 (12.1)
 Cardiac implantable electronic devices 649 (8.6)
 Coronary artery disease 970 (12.8)
 Previous PCI 108 (1.4)
 Previous CABG 183 (2.4)
 Congenital heart disease 42 (1.0)
 Cancer 1018 (13.4)
 COPD 702 (9.3)
 Opioid consumption 103 (1.4)
 Chronic hepatic disease 366 (4.8)
Infectious agents, n (%)
 Staphylococcus 1242 (16.4)
 Streptococcus 1030 (13.6)
 Enterococcus 535 (7.1)
 Gram-negative 898 (11.9)
 Anaerobes 20 (0.3)
 Fungi 10 (0.1)
 Brucella 9 (0.1)
Table 2 IE related complications, cardiac surgery and mortality 
during incident hospitalization for IE
CNS central nervous system
2010–2018
In-hospital complications/outcomes, n (%)
 Heart failure 2232 (29.5)
 Sepsis 937 (12.4)
 Ischemic CNS event 743 (9.8)
 Hemorrhagic CNS event 204 (2.7)
 Non-neurological systemic embolism 97 (1.3)
 Splenic abscess 73 (1.0)
 CNS abscess/meningitis 91 (1.2)
 Acute renal failure 819 (10.8)
 Acute myocardial infarct 220 (2.9)
 Cardiac surgery, incident episode, n (%) 937 (12.4)
 In-hospital death, incident episode, n (%) 1513 (20.0)
One-year follow-up, n (%) 6061
 30-day re-hospitalization 294 (4.8)
 1-year re-hospitalization 599 (9.8)
Total cardiac surgery—including 1-year follow-up, n (%) 998 (13.2)
Death—including 1-year follow-up, n (%) 1611 (21.2)
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Table 3 Progression of IE patients by clinical, microbiological and outcomes
2010 2011 2012 2013 2014 2015 2016 2017 2018 p
Total cohort n = 629 n = 761 n = 812 n = 854 n = 903 n = 967 n = 903 n = 892 n = 853
Male 367 450 452 480 520 539 496 527 477 0.44
58.3% 59.1% 55.7% 56.2% 57.6% 55.7% 54.9% 59.1% 55.9%
< 18 years 9 11 8 7 10 9 10 12 15 < 0.001
1.4% 1.4% 1.0% 0.8% 1.1% 0.9% 1.1% 1.3% 1.8%
18–39 years 63 76 69 57 56 56 51 36 39
10.0% 10.0% 8.5% 6.7% 6.2% 5.8% 5.6% 4.0% 4.6%
40–59 years 105 164 147 143 144 159 126 146 119
16.7% 21.6% 18.1% 16.7% 15.9% 16.4% 14.0% 16.4% 14.0%
60–79  years 316 353 383 394 433 429 433 434 390
50.2% 46.4% 47.2% 46.1% 48.0% 44.4% 48.0% 48.7% 45.7%
≥ 80 years 136 157 205 253 260 314 283 264 290
21.6% 20.6% 25.2% 29.6% 28.8% 32.5% 31.3% 29.6% 34.0%
Diabetes mellitus 129 182 204 225 241 283 243 262 247 0.001
20.5% 23.9% 25.1% 26.3% 26.7% 29.3% 26.9% 29.4% 29.0%
Cardiac valve disease 120 159 163 174 189 212 179 224 170 0.13
19.1% 20.9% 20.1% 20.4% 20.9% 21.9% 19.8% 25.1% 19.9%
Rheumatic valve disease 53 74 81 79 109 94 86 74 59 0.12
8.4% 9.7% 10.0% 9.3% 12.1% 9.7% 9.5% 8. .3% 6.9%
Atrial fibrillation 139 178 221 230 267 301 268 138 134 < 0.001
22.1% 23.4% 27.2% 26.9% 29.6% 31.1% 29.7% 15.5% 15.7%
Arterial hypertension 185 222 284 295 332 368 350 390 402 < 0.001
29.4% 29.2% 35.0% 34.5% 36.8% 38.1% 38.8% 43.7% 47.1%
Chronic renal failure 49 52 43 82 88 98 114 189 172 < 0.001
7.8% 6.8% 5.3% 9.6% 9.7% 10.1% 12.6% 21.2% 20.2%
HIV 19 16 15 11 17 16 15 10 14 0.030
3.0% 2.1% 1.8% 1.3% 1.9% 1.7% 1.7% 1.1% 1.6%
Cancer 86 97 120 121 150 147 122 96 79 0.004
13.7% 12.7% 14.8% 14.2% 16.6% 15.2% 13.5% 10.8% 9.3%
COPD 62 75 74 87 109 120 85 43 47 < 0.001
9.9% 9.9% 9.1% 10.2% 12.1% 12.4% 9.4% 4.8% 5.5%
Cardiac valve prosthesis 70 90 98 98 86 116 109 132 115 0.030
11.1% 11.8% 12.1% 11.5% 9.5% 12.0% 12.1% 14.8% 13.5%
Cardiac device 39 61 63 58 61 79 88 87 113 < 0.001
6.2% 8.0% 7.8% 6.8% 6.8% 8.2% 9.7% 9.8% 13.2%
CAD 60 81 107 97 130 130 122 114 129 0.001
9.5% 10.6% 13.2% 11.4% 14.4% 13.4% 13.5% 12.8% 15.1%
Chronic hepatic disease 30 41 39 45 62 47 42 28 32 0.03
4.8% 5.4% 4.8% 5.3% 6.9% 4.9% 4.7% 3.1% 3.8%
Staphylococcus 95 114 115 130 145 158 145 170 170 < 0.001
15.1% 15.0% 14.2% 15.2% 16.1% 16.3% 16.1% 19.1% 19.9%
Streptococcus 83 124 114 120 149 124 125 104 87 0.002
13.2% 16.3% 14.0% 14.1% 16.5% 12.8% 13.8% 11.7% 10.2%
Enterococcus 40 53 57 54 74 63 75 61 58 0.60
6.4% 7.0% 7.0% 6.3% 8.2% 6.5% 8.3% 6.8% 6.8%
Gram negatives 57 87 98 104 132 140 123 65 92 0.69
9.1% 11.4% 12.1% 12.2% 14.6% 14.5% 13.6% 7.3% 10.8%
Acute MI 12 30 27 20 21 30 31 28 21 0.96
1.9% 3.9% 3.3% 2.3% 2.3% 3.1% 3.4% 3.1% 2.5%
Page 6 of 12Sousa et al. BMC Cardiovasc Disord          (2021) 21:138 
2015 (9.35 per 100,000 inhabitants)—a deceleration was 
noted afterward.
The same trend was observed regarding sex-spe-
cific incidence in males and females and older patients 
(≥ 40 years old). Regarding younger patients, a declining 
tendency is noted quite early (from 2011 onwards)—see 
Fig. 3b.
Prediction factors related to hospital mortality in IE
IE-specific in-hospital mortality rate significantly 
increased from 2010 (17.5%) to 2018 (24.5%)—see Fig. 1 
and Table 3.
Logistic regression analysis for in-hospital mortality 
is summarized in Table  5. All 27 variables stated in the 
first column were available for analysis for all individuals. 
Table 3 (continued)
2010 2011 2012 2013 2014 2015 2016 2017 2018 p
HF 179 193 238 256 264 316 303 253 230 0.28
28.5% 25.4% 29.3% 30.0% 29.2% 32.7% 33.6% 28.4% 27.0%
Ischemic stroke 50 64 75 71 100 91 95 92 68 0.28
7.9% 8.4% 9.2% 8.3% 11.1% 9.4% 10.5% 10.3% 8.0%
Hemorrhagic stroke 11 18 24 20 31 22 25 34 19 0.24
1.7% 2.4% 3.0% 23% 3.4% 2.3% 2.8% 3.8% 2.2%
Systemic embolism 2 1 4 8 2 8 15 31 26 < 0.001
0.3% 0.1% 0.5% 0.9% 0.2% 0.8% 1.7% 3.5% 3.0%
Splenic abscess 4 11 10 10 16 11 9 1 1 0.006
0.6% 1.4% 1.2% 1.2% 1.8% 1.1% 1.0% 0.1% 0.1%
Acute renal failure 68 88 63 78 80 70 81 141 150 < 0.001
10.8% 11.6% 7.8% 9.1% 8.9% 7.2% 9.0% 15.8% 17.6%
Sepsis 64 102 113 101 128 142 102 108 108 0.88
10.2% 13.4% 13.9% 11.8% 14.2% 14.7% 11.3% 12.1% 12.7%
In hospital IE related complications 305 381 428 435 479 540 504 478 445 0.01
48.5% 50.1% 52.7% 50.9% 53.0% 55.8% 55.8% 53.6% 52.2%
Cardiac valve surgery 64 92 107 106 122 112 94 130 110 0.25
10.2% 12.1% 13.2% 12.4% 13.5% 11.6% 10.4% 14.6% 12.9%
Death 110 151 149 153 164 188 185 204 209 < 0.001
17.5% 19.8% 18.3% 17.9% 18.2% 19.4% 20.5% 22.9% 24.5%
CAD Coronary Artery Disease, COPD chronic obstructive pulmonary disease, HF heart failure, HIV human immunodeficiency virus, MI myocardial infarction
Values in Italic highlight p values < 0.05
Fig. 1 Evolution of annual in-hospital surgical rate and mortality rate (%) among patients hospitalized with IE, in Portugal, 2010–2018
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Table 4 Incidence evolution of IE, by total cohort, by age, and by sex
Incidences are reported per 100,000 inhabitants
Total Age group (years) Sex
< 18 18–39 40–59 60–79 ≥ 80 Male Female
2010 6.25 0.38 2.16 3.73 15.78 27.10 7.64 4.99
2011 7.59 0.47 2.66 5.80 17.45 29.97 9.40 5.93
2012 8.14 0.35 2.48 5.18 18.76 37.85 9.51 6.89
2013 8.61 0.31 2.11 5.02 19.16 45.19 10.18 7.19
2014 9.15 0.45 2.13 5.04 20.86 45.04 11.11 7.38
2015 9.35 0.38 2.06 5.26 19.69 51.10 11.00 7.87
2016 8.76 0.43 1.92 4.14 19.71 44.71 10.16 7.50
2017 8.67 0.52 1.38 4.78 19.50 40.81 10.83 6.73
2018 8.30 0.66 1.51 3.89 17.32 43.84 9.83 6.93
Fig. 2 Global and sex-specific annual incidence of IE evolution, in Portugal, from 2010 to 2018
Fig. 3 Nine-year period average age-specific incidence of IE (a) and group age-specific annual incidence of IE (b) per 100,000 habitants, in Portugal, 
from 2010 to 2018
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Independent prognosticators of in-hospital mortality 
were the presence of previous cardiac valve disease, can-
cer, chronic renal or hepatic disease, HIV, Staphylococcus 
or Gram-negative infection, acute myocardial infarction, 
heart failure, older age (specifically after 80  years old), 
ischemic or hemorrhagic stroke, sepsis and acute renal 
failure, the last were the strongest predictors. Younger 
age (particularly less than 40  years old) was a protec-
tive factor regarding fatal outcome. Cardiac surgery also 
had a protective effect on in-hospital mortality—see 
Table 5—odds ratio = 0.69 (95% CI 0.55–0.86, p = 0.001).
Discussion
Our study identified 7574 patients with incident IE hos-
pitalized between 2010 and 2018, in Portugal. Four main 
extrapolations were obtained from this analysis. First, the 
annual crude populational incidence of IE in Portugal 
averaged 8.3 cases per 100,000 habitants (95% CI 7.59–
9.03), with a general growing trend. Second, Staphylococ-
cus was the most prevalent infectious agent in this study. 
Third, the surgical intervention rate was slightly lower 
than expected but its protective effect towards prognosis 
was demonstrated. Finally, this recent analysis confirms 
that despite all efforts to improve its prognosis, a still too 
high mortality was noted, with a rising trend.
Incidence estimation can only be performed using 
populational based data. With regards to IE, popula-
tional surveys are scarce and with significant varia-
tions regarding methodology and results. The reported 
incidence of IE among different studies is not entirely 
similar ranging between 3 and 15 cases per 100,000 in 
population-based studies [15–27], with considerable 
differences noted even in similar countries [28]. Still, 
the findings in Portugal are consistent with the already 
described values. Additionally, an upper trend in inci-
dent IE was noted between 2010 and 2018. The strength 
of this observation is probably restricted by the fact 
that we are analyzing a short period. Nevertheless, this 
has been observed in several developed countries such 
as Denmark, Italy, England, Spain, Germany, or the 
Netherlands in the past two decades. This tendency was 
not noted, however, in other countries such as France, 
Australia, Scotland or the United States of America 
(USA) [16, 20]. Reasons to explain this global upper 
trend in IE incidence in Portugal are various, although 
some may be speculative as this study does not allow 
for a cause-effect analysis. Portugal has experienced a 
gradual increase in life expectancy of the population 
[29], population aging [30] with a sustained increase 
in the aging index of the population [31]. This, adding 
to a growing proportion of patients with comorbidi-
ties associated with an increased rate of invasive medi-
cal procedures (cardiac and non-cardiac) can partially 
explain the observed tendency. Of course, the improve-
ment in microbiology, imaging techniques and medical 
expertise (clinician’s awareness and technical speciali-
zation) that are available in the public health system to 
diagnose IE can also contribute to the observed trend 
in developed countries.
Regarding microbiology, the data retrieved from dis-
charge notes were scarce (49.5% of the total cohort), 
probably a result of underreporting—this has been noted 
in other populational studies such as in Fedeli et al. [18] 
or Shah et al. [27]. Infectious agents such as Staphylococ-
cus spp. and Streptococcus spp. were the most prevalent 
in this analysis, with a mild predominance of the former, 
which is according to other tertiary hospitals series [18, 
29, 32]. In fact, in developed countries Staphylococcus 
has replaced Streptococcus as the most prevalent infec-
tious agent causing IE in the last decades, mainly justi-
fied by an increase in invasive medical procedures in the 
general population as well as a significant population of 
IV drug use. Our data does not allow for analysis regard-
ing the source of IE (community versus healthcare-asso-
ciated). On the other hand, the low percentage of patients 
with opioid consumption or HIV in our cohort is prob-
ably related to underreporting or underdiagnosis at the 
time of hospitalization. Unpredictably, gram-negative 
bacteria were the third most frequent cause of IE in our 
study (11.9%), followed by Enterococcus.
The increasing role of cardiac surgery in IE manage-
ment is well documented in all scientific guidelines [7, 
33]. The surgical rate in other populational studies ranged 
from 15 to nearly 50%; yet, the most recent populational 
series that included patients hospitalized after 2010 
reported heterogeneous surgical rates of 10.6–13.3% 
(Toyoda et al. [24], USA), 3.8–6.3% (Shah et al. [27], Scot-
land), 23% (Olmos et  al. [26], Spain) and 46.5% (Cresti 
et al. [25], Italy). Our analysis presented marginally lower 
values of surgical rate (up to 13.2% at one-year follow-up 
had had valve surgery), which may be a consequence of 
an older cohort, with significant comorbidities and a high 
rate of noncardiac complications as has been described 
individually in Portuguese single-center surveys [8]. Also, 
a part of the total cohort may have had surgery after dis-
charge from the incident hospitalization and the IE code 
may have been underreported in the surgical hospitaliza-
tion report with loss of that data during this evaluation. 
An important aspect of our analysis was the demonstra-
tion of a clear clinical benefit of surgery which was also 
noted in the ICE registry [32], in a metanalysis by Head 
et  al. [34] and in other tertiary referral centers surveys 
[10, 11, 35, 36]. Still, a general described temporal trend 
is on stability [18, 20, 32, 37], which is consistent with our 
data, despite more recent series reporting an increasing 
tendency in Spain [26] and the USA [38].
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One-fifth of the cohort died during the index hospi-
talization. This is in accordance with other already men-
tioned populational series. Trend analysis revealed an 
upper tendency consistent with Italian scenario [18, 25] 
whereas in Denmark [15], Spain [26] and the USA [38] a 
decrease was registered. Half the cohort presented related 
complications, being heart failure the most prevalent situ-
ation. An increase in the rate of prognostic factors such as 
older age, comorbidities (cancer or renal chronic disease), 
infection by Staphylococcus and the presence of IE related 
in-hospital complications may justify a higher complex-
ity in IE cases that could thus partially explain this higher 
mortality during the observed period. This once again 
confirms the malignant nature of this disease—in fact, 
the multisystemic nature of the presented complications 
(cardiac, infectious, neurological, renal) is an argument 
in favor of having a multidisciplinary team of specialists 
managing this disease in dedicated centers to improve its 
prognosis at an individual level.
Finally, nearly 10% of the surviving cohort after the 
first hospitalization with IE were readmitted during the 
first year. Few studies have analyzed this specific fea-
ture. Morita et  al. [39] concluded that nearly 25% of 
their cohort were readmitted during the first 30  days 
post-discharge. The fact that most of our patients were 
discharged home or to rehabilitation or palliative care 
institutions and that the length of hospital stay was con-
siderably higher in our study (median 21  days in our 
study versus 10 days at Morita et al. study) may have con-
tributed to this disparity.
The general growing incidence of IE in a contemporary 
cohort in Portugal, the need for prolonged hospitaliza-
tion, with a significant rate of complications and mor-
tality highlight that IE should be a clinical and national 
priority.
Limitations
Our study has several limitations.
First, our data were obtained from ICD coded infor-
mation obtained from discharge reports. Regarding the 
medical information included in the discharge report, 
its accuracy could not be verified at an individual patient 
level and therefore incomplete or erroneous information 
could have been included, which could have contributed 
to an overestimation of the IE cases. Regarding the ICD 
coding that was transferred for an administrative data-
set, in Portugal, this process is performed by specifically 
trained physicians and submitted for an external audition 
for quality assurance. Still, coding errors or misclassifica-
tions may have occurred.
Second, as the study was retrospective and based on 
administrative data, identification of specific clinical and 
surgical factors or confounders (origin of IE: community 
versus health care, frailty index, antibiotic coverage, for-
mal clinical indication for surgery, etc.) that could have a 
role in explaining some of the shifts observed regarding 
incidence, surgical rate or in-hospital mortality was lim-
ited. Also, the underreporting of relevant concomitant 
diagnoses could have taken place.
Third, the population of Madeira and Azores islands 
was not included in this analysis between 2010 and 2014 
and the information regarding private hospitals was not 
included in this analysis which may have underestimated 
the number of real IE cases.
Fourth, we assumed that the infectious agents identi-
fied through the ICD coding were the causative agents 
of IE but this information was not validated individually. 
Also, half the patients did not have information on the 
infectious agent either because it was a negative blood 
culture IE or because it was underreported, and this was 
unfeasible to ascertain.
Finally, a selection bias for surgical intervention could 
have been present as high-risk patients with an indica-
tion for surgery but refused or that died before surgery 
were not identified.
Conclusions
Between 2010 and 2018 in Portugal, the incidence of 
infective endocarditis demonstrated a global increase 
with a deceleration in more recent years, a significant 
rate of in-hospital complications, a mildly lower than 
expected stable surgical rate and a still too high and 
growing mortality rate.
The  need to analyze and eventually improve existing 
advanced clinical protocols, hospital circuits for these 
patients, and the specialization of local multidisciplinary 
clinical teams is warranted. Additionally, optimization 
of national healthcare organization through the defini-
tion of specific national referral centers should be sought. 
Lastly, a better understanding of epidemiology is crucial 
in justifying and promoting favorable national health pol-
icies. This can be achieved through the implementation 
of a national registry that can prospectively describe IE´s 
diagnosis and management, the promotion of patients 
and physicians´ education/awareness programs, and the 
active intervention on risk factors that are amenable to be 
altered.
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